Literature DB >> 14999392

[New therapeutic strategies for the different subtypes of urticaria].

U Raap1, T Liekenbröcker, D Wieczorek, A Kapp, B Wedi.   

Abstract

Urticaria is one of the most common skin diseases. It is divided into several categories including acute and chronic urticaria as well as physical urticaria and special subtypes such as cholinergic and autoimmune urticaria. The causes of urticaria are multiple. In more than 80%, urticaria is triggered by an inflammatory focus, a subclinical infection or autoimmune actions. In addition, non-specific pharmacological or toxin-mediated release of inflammatory mediators from basophils or mast cells can also trigger urticaria. These new aspects in the pathophysiology of urticaria suggest new and promising therapeutic strategies. The first line treatment of urticaria still consists of non-sedating H1-antihistamines. Since urticaria has a profound impact on quality of life, effective treatment is very important. We consider new therapeutic options based on our long-term experience in treating patients with urticaria.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14999392     DOI: 10.1007/s00105-004-0693-8

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  32 in total

Review 1.  Pathways for bradykinin formation and inflammatory disease.

Authors:  Allen P Kaplan; Kusumam Joseph; Michael Silverberg
Journal:  J Allergy Clin Immunol       Date:  2002-02       Impact factor: 10.793

2.  Aromatic components of food as novel eliciting factors of pseudoallergic reactions in chronic urticaria.

Authors:  Torsten Zuberbier; Christine Pfrommer; Kirsten Specht; Stefan Vieths; Renate Bastl-Borrmann; Margitta Worm; Beate M Henz
Journal:  J Allergy Clin Immunol       Date:  2002-02       Impact factor: 10.793

3.  [Epidemiology and clinical aspects of cold urticaria].

Authors:  A Möller; M Henning; T Zuberbier; B M Czarnetzki-Henz
Journal:  Hautarzt       Date:  1996-07       Impact factor: 0.751

Review 4.  [Urticaria. New developments and perspectives].

Authors:  B M Henz; T Zuberbier
Journal:  Hautarzt       Date:  2000-05       Impact factor: 0.751

Review 5.  Ebastine: an update of its use in allergic disorders.

Authors:  M Hurst; C M Spencer
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

6.  [Round Table: Urticaria in relation to infections].

Authors:  A Bilbao; J M García; I Pocheville; C Gutiérrez; J M Corral; A Samper; G Rubio; J Benito; P Villas; D Fernández; J I Pijoán
Journal:  Allergol Immunopathol (Madr)       Date:  1999 Mar-Apr       Impact factor: 1.667

7.  Fexofenadine in chronic idiopathic urticaria: a clinical and immunohistochemical evaluation.

Authors:  G. A. Vena; N. Cassano; M. Filieri; R. Filotico; V. D'Argento; C. Coviello
Journal:  Int J Immunopathol Pharmacol       Date:  2002 Sep-Dec       Impact factor: 3.219

8.  Acute urticaria associated with streptococcal infection.

Authors:  D E Schuller; S M Elvey
Journal:  Pediatrics       Date:  1980-03       Impact factor: 7.124

9.  Prevalence of Helicobacter pylori-associated gastritis in chronic urticaria.

Authors:  B Wedi; S Wagner; T Werfel; M P Manns; A Kapp
Journal:  Int Arch Allergy Immunol       Date:  1998-08       Impact factor: 2.749

Review 10.  Urticaria.

Authors:  T Zuberbier
Journal:  Allergy       Date:  2003-12       Impact factor: 13.146

View more
  3 in total

Review 1.  [Current position of the role of allergic and non-allergic food hypersensitivity in urticaria].

Authors:  B Wedi; A Kapp
Journal:  Hautarzt       Date:  2006-02       Impact factor: 0.751

2.  [Modern diagnosis and treatment of urticaria: five case reports].

Authors:  D Wieczorek; U Raap; A Kapp; B Wedi
Journal:  Hautarzt       Date:  2007-04       Impact factor: 0.751

3.  [Cold-induced urticaria and angioedema. Classification, diagnosis and therapy].

Authors:  K Krause; F Degener; S Altrichter; E Ardelean; D Kalogeromitros; M Magerl; M Metz; F Siebenhaar; K Weller; M Maurer
Journal:  Hautarzt       Date:  2010-09       Impact factor: 0.751

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.